Startup · $211.3m raised
Brisbane, QLD
Every investor coverage indicates participated in a round Vaxxas raised.
| Investor | Rounds | Invested |
|---|---|---|
| Advanced Manufacturing Growth Centre | Grant | - |
| Australian Government | Grant · Grant | - |
| BARDA | Series D+ · Grant | $3,200,000 |
| Brandon Capital | Series A | - |
| Brandon Capital-Hostplus | Series D+ | - |
| CEPI | Grant | $6,400,000 |
| Coalition for Epidemic Preparedness Innovations | Grant | - |
| Commercialisation Fund | Grant | - |
| Gates Foundation | Grant | - |
| Healthcare Ventures | Series A | - |
| LGT Crestone | Series D+ | - |
| Medical Research Commercialisation Fund (MRCF) | Series A | - |
| Modern Manufacturing Initiative | Grant · Grant | $12,600,000 |
| MSD | Unnamed stage | - |
| OneVentures | Series D+ · Unnamed stage · Series B · Series A | - |
| SPRIM Global Investments | Series D+ · Venture debt | - |
| UniQuest | Unnamed stage | - |
| Vaxxas from the US Biomedical Advanced Research and Development Authority | Grant | $3,230,000 |
Investors whose own portfolio pages list Vaxxas, even though we haven't found any coverage of the round yet.
Companies Vaxxas acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Vaxxas. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
A fund's insights listing: its headline flags Vaxxas naming an ex-Merck vaccines chief as CEO, while linked teasers report Eucalyptus' $1.6b sale and Accel-KKR's takeover of Phocas.
Also OneVentures portfolio·AFR Technology·phocassoftware.com
A quarterly report on the Australian venture market finds Q3 2025 investment passed a billion dollars, led by a Singapore data centre company's raise, with AI drawing premium valuations and bubble warnings.
Cut Through Venture's quarterly report counts roughly $1 billion over 116 Australian venture rounds in 3Q 2025; deep-tech sectors dominated, Firmus Technologies' $330M raise was largest, and early-stage valuations climbed.
Curated OneVentures roundup: Eucalyptus sold to a New York-listed healthcare group for $1.6 billion and Vaxxas named ex-Merck vaccines president David Peacock as CEO, plus patent-cliff and women-in-tech links.
Weekly roundup detailing five Australian raises: Vaxxas' Series D plus debt facility amid executive changes, Skutopia's growth round, Send Payments' backing and CEO change, Apate.ai's seed, and Coursebox's seed.
Also Startup Daily·SmartCompany·Australian FinTech·Dealroom·Startup Daily
Australian biotech Vaxxas secured a Series D plus a debt facility while overhauling leadership: a new chair, founding CEO shifting to an advisory role, and CFO made redundant amid job cuts.
Also Business News Australia·SmartCompany·Cut Through Venture·Startup Daily·Startup Daily·SmartCompany·Startup Daily
Vaxxas announced a roughly A$90m financing — Series D equity led by SPRIM Global Investments plus debt — to advance its needle-free vaccine patch, alongside leadership changes including a new chair.
Brandon Capital has completed a A$439 million final close for its sixth life sciences fund, bringing the National Reconstruction Fund Corporation and WA Government in alongside backers such as HESTA, Hostplus, CSL and QIC.
Vaxxas has finished enrolling 258 volunteers in its Phase I trial of a needle-free HD-MAP avian flu vaccine, funded by a US BARDA contract, with early findings due mid-2025.
Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·labonline.com.au·SmartCompany·SmartCompany·labonline.com.au
Vaxxas has filled its 258-person Phase I trial of a needle-free avian flu vaccine patch, run under a US$28.5 million US government contract; the post also recounts the company's early backing.
Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·labonline.com.au·SmartCompany·SmartCompany·labonline.com.au
Roundup of short industry items: Element 25 and Vaxxas win US government grants, Orthocell gets an R&D refund, Convergence Medical completes its Series A, and Monique Conheady takes a Hysata board seat.
Also Startup Daily
Vaxxas has won the concept stage of BARDA's Patch Forward Prize, earning US$2 million (A$3.2 million) to progress its microarray patch vaccine platform alongside the University of Queensland's BASE facility.
Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·labonline.com.au·SmartCompany·SmartCompany·labonline.com.au
Vaxxas wins US$2 million as a concept-stage winner of BARDA's prize to advance its skin-patch vaccine platform with UQ's BASE facility; the article also recalls early backing by OneVentures, Brandon Capital and HealthCare Ventures.
Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·@AuManufacturing·@AuManufacturing·Business News Australia
Weekly roundup covering seven Australian companies' fresh capital: EV charging, satellite IoT, sovereign cloud, wearables, workplace messaging, plus two crowdfunding raises on Birchal.
Also Startup Daily·Startup Daily·@AuManufacturing·@AuManufacturing
Vaxxas, a Brisbane biotech, has taken a worldwide licence from the US NIH to an RSV antigen candidate, aiming to advance it toward a Phase I study; another trial runs with BARDA funding.
OneVentures' insights feed highlights a pharma patent-cliff analysis, an AFR feature, Eucalyptus' $1.6b sale to a US healthcare group, and Vaxxas naming David Peacock chief executive.
OneVentures insights listing linking to coverage of Eucalyptus's $1.6b sale to a US-listed healthcare company and Vaxxas hiring a former Merck vaccines president as CEO.
Brisbane surgical-robotics startup Convergence Medical wins a US regulator's fast-track designation for its arthroscopic robot; the piece recalls two recent raises totalling $3 million and a new chief medical officer hire.
Publisher's post about a venture firm multiplying its money thirteen-fold on one startup bet; the page also carries linked reports of Eucalyptus's $1.6 billion sale and Vaxxas naming David Peacock chief executive.
Vaxxas reports positive Phase I results for its needle-free skin-patch delivery of a measles-rubella vaccine, with Gates Foundation grant funding and a planned PATH-sponsored Phase I/II trial in The Gambia.
Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·labonline.com.au·SmartCompany·SmartCompany·labonline.com.au
Brisbane vaccine patch maker Vaxxas won a $5.4 million Wellcome grant for studies and a Phase I trial of a typhoid vaccine using its HD-MAP technology, developed with SK bioscience.
OneVentures links out to Vaxxas's announcement that the biotech has opened a manufacturing site for its needle-free vaccine patch.
Vaxxas, with Queensland Government backing, has opened its Brisbane global headquarters and vaccine patch manufacturing facility, supported by state and federal government funding.
Vaxxas reports encouraging interim Phase I results for its needle-free microarray-patch COVID-19 vaccine, with strong antibody responses and no serious adverse events, ahead of planned regulatory applications in Australia and the US.
Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·labonline.com.au·SmartCompany·SmartCompany·labonline.com.au
Vaxxas hires former Pfizer medical executive Dr Rochelle Chaiken as its chief medical officer; the announcement also recounts the biotech's founding financing and later rounds.
Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·labonline.com.au·SmartCompany·SmartCompany·labonline.com.au
Vaxxas has appointed 23-year Pfizer veteran Dr Rochelle Chaiken as chief medical officer; the announcement also recaps the vaccine-patch company's early backing by OneVentures, Brandon Capital and others.
Vaxxas appointed Dr Rochelle Chaiken, a former Pfizer executive, as Chief Medical Officer, and reported positive interim Phase 1 trial results for its needle-free COVID-19 vaccine patch at the Boston biotech convention.
Roundup covering an SME sentiment survey, Renewable Metals winning a Supercharge Australia award, a new Queensland trade commissioner, an FFI green hydrogen power deal, a Siemens emissions pilot, and a CDU drones grant.
Vaxxas has begun an Australian Phase I trial of its needle-free influenza vaccine patch. The article also recalls the company's founding equity financing led by OneVentures with Brandon Capital Partners and other co-investors.
Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·labonline.com.au·SmartCompany·SmartCompany·labonline.com.au
Techboard's monthly roundup catalogues December 2022 startup raises, led by Synchron's $110m Series C, with health and biotech taking the largest share and 55 funding events captured totalling $546m.
Roundup of manufacturing news: Vaxxas secures CEPI funding and a CRC-P grant, Hastings gains an increased NAIF loan, Bio-Gene receives an R&D tax incentive, plus jobs data and a skills consultation.
Vaxxas partners with CEPI, which will fund preclinical testing of its needle-free vaccine patch for mRNA vaccines, work that could remove cold-storage needs and widen global access to such vaccines.
Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·labonline.com.au·SmartCompany·SmartCompany·labonline.com.au·@AuManufacturing·@AuManufacturing
The federal government announced grants supporting 19 Australian manufacturing collaboration projects, including Dovetail Electric Aviation's electric aircraft conversions, Vaxxas' vaccine patch, and Whiteley's anti-biofilm wound treatments, while opening the next CRC-P round.
Also @AuManufacturing·SmartCompany·Startup Daily·@AuManufacturing·@AuManufacturing
A weekly roundup reporting ten Australian startup funding rounds totalling roughly eighty million dollars, spanning insurance tech, biotech, process mining, connectivity and food, with several female-founded companies among the recipients.
A OneVentures post reports a needle-free vaccine developer raising A$34 million; linked items on the page note Eucalyptus's $1.6 billion sale to a US-listed healthcare firm and Vaxxas naming David Peacock chief executive.
Also Blackbird Ventures portfolio·Startup Daily·SmartCompany·Dealroom·SmartCompany·Startup Daily·AFR Technology·Dealroom·Forbes Australia
Vaxxas completed a US$23 million (A$34 million) financing led by OneVentures and UniQuest to advance its needle-free vaccine clinical programs, including a COVID-19 candidate, with board members, management and individual investors also participating.
Also Brandon Capital portfolio·OneVentures portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·labonline.com.au·SmartCompany·SmartCompany·SmartCompany·Techboard·labonline.com.au·@AuManufacturing·@AuManufacturing
Vaxxas has begun an Australian Phase I trial of its needle-free COVID-19 vaccine patch, built on a University of Texas at Austin candidate; the article also recalls the company's early financings led by OneVentures.
Vaxxas has begun an Australian Phase I trial of its needle-free COVID-19 vaccine patch; the article also recalls the company's founding financing led by OneVentures with Brandon Capital and other co-investors.
Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·labonline.com.au·SmartCompany·SmartCompany·labonline.com.au
Vaxxas has begun a phase one trial in Australia of its needle-free COVID-19 vaccine patch. The Brisbane company, backed by OneVentures, Brandon Capital and others, has hired Scott Fry from Ellume as COO.
Brisbane biotech Vaxxas has begun human testing of its microneedle patch for COVID-19 vaccination and plans a phase two study; the venture-backed company has raised over $66 million.